[go: up one dir, main page]

ES2468665B1 - Pharmaceutical composition of chondroitin sulfate and celecoxib - Google Patents

Pharmaceutical composition of chondroitin sulfate and celecoxib Download PDF

Info

Publication number
ES2468665B1
ES2468665B1 ES201201233A ES201201233A ES2468665B1 ES 2468665 B1 ES2468665 B1 ES 2468665B1 ES 201201233 A ES201201233 A ES 201201233A ES 201201233 A ES201201233 A ES 201201233A ES 2468665 B1 ES2468665 B1 ES 2468665B1
Authority
ES
Spain
Prior art keywords
chondroitin sulfate
celecoxib
pharmaceutical composition
composition
refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201201233A
Other languages
Spanish (es)
Other versions
ES2468665A1 (en
Inventor
Sergio Arroyo Hidalgo
José Miguel RIZO MARTÍNEZ
Antonia Gómez Calvo
Nuria Sanz Menéndez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider SA filed Critical Farmalider SA
Priority to ES201201233A priority Critical patent/ES2468665B1/en
Publication of ES2468665A1 publication Critical patent/ES2468665A1/en
Application granted granted Critical
Publication of ES2468665B1 publication Critical patent/ES2468665B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica de sulfato de condroitina y celocexib.#La presente invención se refiere a una composición farmacéutica de sulfato de condroitina y celecoxib. En particular, se refiere a una composición para administración oral en la que la relación en peso entre sulfato de condroitina y celecoxib está comprendida entre 1,5:1 y 2,5:1, proporción que resulta particularmente eficaz para el tratamiento de cartílagos dañados en pacientes con artrosis. También se refiere a una forma farmacéutica de dosificación unitaria, en particular un comprimido y una cápsula, que comprende una cantidad terapéuticamente efectiva de dicha composición. También se refiere al uso de dicha composición para la preparación de un medicamento para el tratamiento de la artrosis.Pharmaceutical composition of chondroitin sulfate and celocexib. # The present invention relates to a pharmaceutical composition of chondroitin sulfate and celecoxib. In particular, it refers to a composition for oral administration in which the weight ratio between chondroitin sulfate and celecoxib is between 1.5: 1 and 2.5: 1, a proportion that is particularly effective for the treatment of damaged cartilage in patients with osteoarthritis. It also refers to a unit dosage pharmaceutical form, in particular a tablet and a capsule, comprising a therapeutically effective amount of said composition. It also refers to the use of said composition for the preparation of a medicament for the treatment of osteoarthritis.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

Claims (1)



 imagen1image 1 imagen2image2
ES201201233A 2012-12-14 2012-12-14 Pharmaceutical composition of chondroitin sulfate and celecoxib Active ES2468665B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201201233A ES2468665B1 (en) 2012-12-14 2012-12-14 Pharmaceutical composition of chondroitin sulfate and celecoxib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201201233A ES2468665B1 (en) 2012-12-14 2012-12-14 Pharmaceutical composition of chondroitin sulfate and celecoxib

Publications (2)

Publication Number Publication Date
ES2468665A1 ES2468665A1 (en) 2014-06-16
ES2468665B1 true ES2468665B1 (en) 2015-06-11

Family

ID=50896606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201201233A Active ES2468665B1 (en) 2012-12-14 2012-12-14 Pharmaceutical composition of chondroitin sulfate and celecoxib

Country Status (1)

Country Link
ES (1) ES2468665B1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate

Also Published As

Publication number Publication date
ES2468665A1 (en) 2014-06-16

Similar Documents

Publication Publication Date Title
AR115939A2 (en) COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE
JP2013014622A5 (en)
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
CL2015002733A1 (en) Pharmaceutical composition of s-ketamine hydrochloride.
HK1221646A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112012016853A2 (en) "pharmaceutical compositions for oral administration of insulin peptides".
ECSP15039103A (en) MOSAPRIDE SUSTAINED RELEASE FORMULATION PROVIDING CLINICAL AND PHARMACOLOGICAL EFFECTS WITH ONCE DAILY ADMINISTRATION
BR112013016862A2 (en) combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
CL2012001836A1 (en) Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others.
BR112015011430A2 (en) composition for immediate and prolonged release
BR112014005025A2 (en) pharmaceutical composition for use in the treatment of a neurodegenerative disease
BRPI0814666A2 (en) pharmaceutical composition for oral administration, use of a formulation. process for preparing a solid dosage form, and, solid dosage form
ES2445846R1 (en) A pharmaceutical combination composition and its use to prepare a medicament for the treatment of type 1 diabetes and metabolic disorders
CR20140540A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
CL2014001828A1 (en) Dual-release oral dosage system comprising doxylamine and pyridoxine and / or its analogs, metabolites and salts thereof; oral dosage form dual release; pharmaceutical kit; use to relieve symptoms of nausea and vomiting, including those of pregnancy.
BR112014014795A2 (en) immediate release multi-unit pellet system
PE20151543A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF SULPHATE SALTS FOR DUAL USE TABLETS AND METHODS FOR ITS USE
EA201691034A1 (en) COMPOSITIONS IN SOLID SHORT-DOWN SHIPPING FOR ORAL ADMISSION
BR112015022398A8 (en) ondansetron tablet and packaged pharmaceutical preparation
BR112016009214A8 (en) use of a compound for the preparation of a drug for the treatment of muscular dystrophy and pharmaceutical composition
ES2468665B1 (en) Pharmaceutical composition of chondroitin sulfate and celecoxib
ES2422877B1 (en) COMBINATION AND COMPOSITION FOR OBESITY TREATMENT
ES2544780T3 (en) Metadoxine for use as a liver fibrosis inhibitor
MX2015015681A (en) Pharmaceutical composition comprising fingolimod.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2468665

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150611